Kineta, Inc. (KA)
NASDAQ: KA · IEX Real-Time Price · USD
0.704
+0.017 (2.54%)
Jul 22, 2024, 9:54 AM EDT - Market open
Kineta Employees
As of December 31, 2023, Kineta had 13 total employees, including 11 full-time and 2 part-time employees. The number of employees increased by 1 or 8.33% compared to the previous year.
Employees
13
Change (1Y)
1
Growth (1Y)
8.33%
Revenue / Employee
$397,000
Profits / Employee
-$1,375,846
Market Cap
8.57M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13 | 1 | 8.33% |
Dec 31, 2022 | 12 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Syra Health | 162 |
Zhongchao | 142 |
Vivos Therapeutics | 123 |
Mainz Biomed B.V. | 71 |
iCoreConnect | 70 |
Molecular Templates | 62 |
Organovo Holdings | 20 |
Shuttle Pharmaceuticals Holdings | 8 |
KA News
- 14 days ago - Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences - GlobeNewsWire
- 14 days ago - TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor - PRNewsWire
- 2 months ago - Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities - GlobeNewsWire
- 3 months ago - Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial - GlobeNewsWire
- 4 months ago - Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported - GlobeNewsWire
- 5 months ago - Kineta Announces Restructuring and Exploration of Strategic Alternatives - GlobeNewsWire
- 5 months ago - Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium - GlobeNewsWire